Share on StockTwits
 

Equities research analysts at Citigroup Inc. raised their target price on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) to $600.00 in a research note issued to investors on Monday, StockRatingsNetwork reports. Citigroup Inc.’s price objective suggests a potential upside of 34.58% from the company’s current price.

In other Intercept Pharmaceuticals news, CMO David Shapiro unloaded 4,928 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $71.85, for a total transaction of $354,076.80. Following the transaction, the chief marketing officer now directly owns 8,663 shares of the company’s stock, valued at approximately $622,437. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of other analysts have also recently weighed in on ICPT. Analysts at Janney Montgomery Scott raised their price target on shares of Intercept Pharmaceuticals to $300.00 in a research note to investors on Friday. Separately, analysts at Needham & Company raised their price target on shares of Intercept Pharmaceuticals from $55.00 to $320.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Oppenheimer raised their price target on shares of Intercept Pharmaceuticals from $94.00 to $360.00 in a research note to investors on Friday. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $413.43.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 16.24% on Monday, hitting $373.44. The stock had a trading volume of 1,747,846 shares. Intercept Pharmaceuticals has a 52 week low of $30.38 and a 52 week high of $497.00. The stock’s 50-day moving average is $78.93 and its 200-day moving average is $58.26. The company’s market cap is $7.220 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings data on Thursday, November 14th. The company reported ($1.65) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.51) by $1.14. During the same quarter in the prior year, the company posted ($1.86) earnings per share. Analysts expect that Intercept Pharmaceuticals will post $-3.56 EPS for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.